GGrantIndex
← Leaderboards

Chris H Wendt

Minneapolis Va Medical Center

$5,946,558
Attributed
$10,154,451
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $832K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,154,451 · 6
VA$0 · 1

By mechanism

R01$8,600,146 · 4
T32$1,156,065 · 1
R21$398,240 · 1
I01$0 · 1

Top collaborators

Most similar at Minneapolis Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungLung DiseasesBiological MarkersCohortChronicReportingPhenotypeInflammatoryBaseProteomeTechnologySmokeSiteMetabolomicsBiomarker DiscoveryProteomicsMultiple OmicsParticipantSphingolipidsSpirometryBioinformaticsPhysiologicalAffectSignal Transduction

Grant awards (27)

CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2025 · VA · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2024 · VA · contact PI
Training in Lung Science$324,046
T32 · FY2023 · HL · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2023 · VA · contact PI
Training in Lung Science$832,019
T32 · FY2022 · HL · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2022 · VA · contact PI
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$667,118
R01 · FY2021 · HL · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2021 · VA · contact PI
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$667,118
R01 · FY2020 · HL · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2020 · VA · contact PI
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$671,673
R01 · FY2019 · HL · contact PI
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$743,025
R01 · FY2018 · HL · contact PI
Identifying imaging-based biomarkers of COPD development through virtual inhalation experiments$228,000
R21 · FY2016 · HL
Identifying imaging-based biomarkers of COPD development through virtual inhalation experiments$170,240
R21 · FY2015 · HL
Common Pathogenetic Mechanisms of Lung Cancer and COPD$697,882
R01 · FY2014 · HL · contact PI
Common Pathogenetic Mechanisms of Lung Cancer and COPD$668,065
R01 · FY2013 · HL · contact PI
Common Pathogenetic Mechanisms of Lung Cancer and COPD$726,338
R01 · FY2012 · HL · contact PI
Common Pathogenetic Mechanisms of Lung Cancer and COPD$718,596
R01 · FY2011 · HL · contact PI
Protein Biomarkers in Lung Allograft Rejection$435,036
R01 · FY2010 · HL · contact PI
Protein Biomarkers in Lung Allograft Rejection$431,340
R01 · FY2009 · HL · contact PI
Protein Biomarkers in Lung Allograft Rejection$25,392
R01 · FY2009 · HL · contact PI
Protein Biomarkers in Lung Allograft Rejection$419,137
R01 · FY2008 · HL · contact PI
Protein Biomarkers in Lung Allograft Rejection$418,091
R01 · FY2007 · HL · contact PI
Na, K-ATPase Regulation by Glucocorticoids in Lung$316,811
R01 · FY2007 · HL · contact PI
Na, K-ATPase Regulation by Glucocorticoids in Lung$326,274
R01 · FY2006 · HL · contact PI
Na, K-ATPase Regulation by Glucocorticoids in Lung$334,125
R01 · FY2005 · HL
Na, K-ATPase Regulation by Glucocorticoids in Lung$334,125
R01 · FY2004 · HL